Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus BioSciences Announces New Employment Inducement Grants
04:01pm, Friday, 20'th Nov 2020
REDWOOD CITY, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective November 19, 2020, the compensation
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2020 Results - Earnings Call Transcript
01:25pm, Sunday, 08'th Nov 2020
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2020 Results - Earnings Call Transcript
Short Interest in CHS Inc 8% Preferred Shares (NASDAQ:CHSCP) Drops By 12.5%
01:12am, Tuesday, 20'th Oct 2020
CHS Inc 8% Preferred Shares (NASDAQ:CHSCP) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 11,200 shares, a d
Oct 09, 2020 (The Expresswire) --
Global “Bevacizumab Biosimilar Market” report provide development plans, market risks, opportunities, challenges and...
Oct 09, 2020 (The Expresswire) --
Global “Bevacizumab Biosimilar Market” report provide development plans, market risks, opportunities, challenges and...
Oct 07, 2020 (Market Insight Reports) --
The Etanercept Market 2020 report is a comprehensive, professional, and in-depth research of the market that...
Coherus Has A High-Quality Business Model And Good Long-Term Potential
12:03pm, Sunday, 13'th Sep 2020
Coherus develops and markets biosimilar versions of blockbuster biologic products. The company is already hugely profitable off of just its first marketed product, but it has five other big pipeline o
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2020 Update
03:50pm, Friday, 04'th Sep 2020
Glenview Capital Management's 13F portfolio value decreased from $3.68B to $3.63B this quarter. The number of positions decreased from 44 to 43.
Global Compound Feeds & Additives Market, 2025 - ResearchAndMarkets.com
12:00am, Tuesday, 25'th Aug 2020
The
Coherus BioSciences Keeps Proving Wall Street Wrong
07:45pm, Tuesday, 11'th Aug 2020
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
Coherus Biosciences (CHRS) Receives a Buy from Maxim Group - Markets
11:45am, Saturday, 08'th Aug 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Coherus Biosciences (CHRS – Research Report) yesterday and set a
Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates
12:10am, Friday, 07'th Aug 2020
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
12:00am, Friday, 07'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
Coherus BioSciences Reports Second Quarter 2020 Financial Results
08:02pm, Thursday, 06'th Aug 2020
– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- C
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
12:00am, Thursday, 06'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
